United States Patent 4,731,478: Tamsulosin Scope, Claims, Expiration, and Patent Landscape

U.S. Patent No. 4,731,478 covers the optically active alpha-adrenergic antagonist later developed as tamsulosin, including the pharmacologically active negative enantiomer and pharmaceutical compositions containing it. The patent was issued on March 15, 1988, and its ordinary 17-year United States patent term expired on March 15, 2005. It does not provide a current U.S. patent barrier to generic tamsulosin entry. [1]

The patent remains important as the foundational compound patent for tamsulosin. Its claims are narrow in chemical identity but commercially significant because they cover the active enantiomer itself rather than only a particular dosage form or manufacturing process.

What drug does U.S. Patent 4,731,478 protect?

The claimed compound is tamsulosin, chemically identified as:

5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide

The marketed product is generally supplied as tamsulosin hydrochloride, the hydrochloride salt of the active compound. The negative optical isomer in claim 2 corresponds to the pharmacologically active tamsulosin enantiomer used in Flomax and generic tamsulosin products.

Patent element	Commercial relevance
2-Methoxybenzenesulfonamide ring	Core aryl sulfonamide pharmacophore
2-(2-Ethoxyphenoxy)ethylamino substituent	Distinctive ether-linked amino side chain
Chiral propyl linkage	Determines enantiomeric identity
Negative optical isomer	Active tamsulosin enantiomer
Pharmaceutical composition	Supports drug-product claims containing the active compound

The patent does not claim a broad class of alpha blockers. It claims a specific optically active chemical entity and compositions containing that entity.

What is the scope of claim 1?

Claim 1 covers:

"Optically active 5-{2-[2-(2-ethoxyphenoxy)ethyl-amino]-2-methylethyl}-2-methoxybenzenesulfonamide."

The principal limitation is optical activity. The claim is directed to an enantiomerically resolved form of the compound, not merely to the racemic mixture.

Does claim 1 cover both enantiomers?

On its face, claim 1 is broader than claim 2. "Optically active" identifies a non-racemic, chirally resolved material but does not specify the sign of rotation. Claim 2 separately covers the negative isomer.

Accordingly, claim 1 can be read as covering:

The negative enantiomer;
The positive enantiomer; and
Potentially compositions containing either optically active form, subject to claim construction and proof of the relevant stereochemical structure.

Claim 1 does not expressly cover every possible derivative, prodrug, salt, ester, or structurally modified analog. Its scope is tied to the named molecular structure.

What does claim 2 protect?

Claim 2 covers the negative isomer of the compound identified in claim 1.

This is the commercially important claim because tamsulosin is the negative enantiomer. Claim 2 therefore targets the active pharmaceutical ingredient rather than merely a racemate or an inactive stereoisomer.

The claim has several practical consequences:

A product containing the claimed negative enantiomer could fall within the claim regardless of whether it is supplied as the free base or a pharmaceutically acceptable salt, depending on claim construction.
A racemic product would raise a different infringement analysis because it contains both enantiomers rather than only the claimed negative isomer.
A process that resolves the racemate into the negative enantiomer would not avoid a product claim directed to the resulting compound.
Enantiomeric purity, absolute configuration, and analytical characterization would be central to any infringement dispute.

The claim does not expressly state a particular enantiomeric purity threshold. That omission could create disputes over whether low-level contamination by the negative isomer is sufficient for infringement, but commercial tamsulosin products contain the active enantiomer as the intended active ingredient.

What do claims 3 and 4 protect?

Claims 3 and 4 are pharmaceutical composition claims.

Claim	Scope
Claim 3	Composition containing an alpha-adrenergic-blocking effective amount of the optically active compound and a pharmaceutically acceptable carrier
Claim 4	Composition of claim 3 containing the negative isomer

These claims add two principal limitations:

The presence of a pharmaceutically acceptable carrier; and
An amount effective to produce alpha-adrenergic blockade.

The composition claims are broader than a claim limited to a particular capsule, tablet, excipient system, dissolution profile, or release mechanism. They do not appear, based on the supplied claim language, to require:

A specific dose;
A specific dosage form;
A specific excipient;
A particular release profile;
A particular particle size;
A particular polymorph;
A particular salt form;
A specific manufacturing process; or
A defined pharmacokinetic profile.

Are tamsulosin hydrochloride products covered?

Tamsulosin hydrochloride is the principal commercial form of tamsulosin. The patent claims identify the active molecular structure without expressly reciting "hydrochloride" in the supplied language.

The legal analysis depends on how "compound" is construed:

If the claim is construed to cover the active moiety and its pharmaceutically acceptable acid-addition salts, tamsulosin hydrochloride would fall within the compound claims.
If the claim is limited to the neutral free-base structure, the hydrochloride salt may require a separate analysis under salt, composition, or literal-equivalence principles.
Claims 3 and 4 present a separate route to infringement because a pharmaceutical composition containing the active tamsulosin moiety may satisfy the composition limitations.

This distinction mattered during the original exclusivity period. It has no current practical impact on ordinary U.S. generic entry because the patent term has expired.

When did U.S. Patent 4,731,478 expire?

The patent issued on March 15, 1988. For a pre-June 8, 1995 U.S. application, the applicable term was generally 17 years from issuance, subject to terminal disclaimers, patent-term adjustments, and other statutory modifications. On that basis, the ordinary expiration date was March 15, 2005. [1]

Event	Date
U.S. patent issuance	March 15, 1988
Ordinary 17-year expiration	March 15, 2005
Current enforceability	Expired
Present Paragraph IV barrier	None from this patent

The patent’s expiration is distinct from regulatory exclusivity. FDA market exclusivity and patent term are separate legal mechanisms. A six-month pediatric extension, if associated with the product’s regulatory records, would not revive the expired patent or create a new patent term. [3]

What was the FDA exclusivity timeline for tamsulosin?

Tamsulosin was approved in the United States under NDA 020579 for Flomax. The product was approved for the signs and symptoms of benign prostatic hyperplasia. [2]

The relevant exclusivity sequence was:

Exclusivity category	General effect
New chemical entity exclusivity	Blocked submission of an ANDA for the statutory period after initial approval
Compound patent protection	Covered the active tamsulosin enantiomer and compositions
Post-expiration generic review	Allowed ANDA applicants to rely on the reference product, subject to patent certifications
Pediatric exclusivity, if applicable	Added regulatory protection to applicable exclusivity or patent rights, but did not create a new compound patent

The FDA Orange Book, rather than the patent document alone, controls the historical record of listed patents and regulatory exclusivity associated with the NDA. [3]

What is the Orange Book status of U.S. Patent 4,731,478?

U.S. Patent 4,731,478 was the foundational listed patent associated with Flomax and tamsulosin. Its patent term has ended. An expired Orange Book-listed patent does not block approval of an ANDA.

The principal Orange Book implications are:

No current patent-based stay can arise solely from this patent.
A generic applicant no longer needs to defeat this patent through a present-day Paragraph IV litigation strategy.
Historical Paragraph IV certifications may have been relevant before expiration.
Later-listed formulation or method-of-use patents must be analyzed separately from the expired compound patent.
Orange Book listing does not itself establish that a patent is currently enforceable.

Which patents protect tamsulosin beyond U.S. Patent 4,731,478?

The patent landscape for tamsulosin can be divided into five categories.

Compound patents

U.S. Patent 4,731,478 is the core compound patent. It covers the optically active tamsulosin structure, the negative enantiomer, and compositions containing it.

Salt patents

A separate patent could claim tamsulosin hydrochloride or another salt as a distinct chemical form. Such a patent would require limitations directed to the salt itself, its preparation, crystallinity, hydration state, or related properties. The supplied claims do not expressly recite a hydrochloride salt.

Formulation patents

Later patents may cover:

Modified-release tamsulosin;
Controlled dissolution;
Specific capsule or tablet systems;
Multiparticulate formulations;
Excipient combinations;
Oral delivery systems;
Stability improvements; or
Defined pharmacokinetic characteristics.

Claims 3 and 4 of Patent 4,731,478 are not formulation-specific. They would not, by themselves, establish a patent on a particular sustained-release technology or capsule architecture.

Method-of-use patents

A method patent could cover administration of tamsulosin for a defined condition, patient population, dosing schedule, or combination therapy. The supplied claims do not contain a treatment method. They are directed to the compound and composition.

Manufacturing and process patents

Process patents may cover:

Enantiomeric resolution;
Chiral synthesis;
Formation of tamsulosin hydrochloride;
Crystallization;
Purification;
Impurity control; or
Scale-up conditions.

Patent 4,731,478, based on the supplied claims, does not claim a manufacturing process. A generic manufacturer could therefore face process or know-how barriers even after the compound patent expired, but those barriers would need to arise from separate, enforceable patents.

How strong was the patent estate for tamsulosin?

The estate anchored by Patent 4,731,478 was strong during its term because claim 2 reached the active enantiomer itself. A generic manufacturer could not avoid the claim merely by changing:

The carrier;
The capsule shell;
The excipient;
The dose;
The manufacturing scale; or
The commercial label.

The principal limitations were chemical identity and stereochemistry. The estate was less comprehensive for delivery technology because the supplied claims do not recite a particular release mechanism, formulation architecture, or manufacturing route.

Strength factor	Assessment
Coverage of active enantiomer	Strong
Coverage of racemate	Limited or disputed
Coverage of salt form	Construction-dependent
Coverage of generic excipients	Broad at composition level
Coverage of specific modified-release systems	Not apparent from supplied claims
Coverage of manufacturing process	Not present in supplied claims
Current enforceability	None; expired

What Paragraph IV challenges and litigation affected tamsulosin?

Paragraph IV certifications historically could have targeted Patent 4,731,478 before its expiration. A generic applicant could assert that the patent was invalid, unenforceable, or would not be infringed. The NDA holder could respond with infringement litigation and potentially obtain a 30-month stay under the Hatch-Waxman framework. [4]

As of the patent’s expiration, Patent 4,731,478 cannot support a new 30-month stay or an injunction against ordinary generic tamsulosin entry. Historical litigation involving tamsulosin may have also concerned later formulation, regulatory, or settlement issues. Those matters should not be attributed to the claims of Patent 4,731,478 without a docket-specific comparison.

No current competitor can be blocked in the United States by this expired patent alone.

What generic launch risks remain?

The main current risks are regulatory and commercial, not infringement risks under Patent 4,731,478.

Regulatory risks

A generic applicant must still establish pharmaceutical equivalence and bioequivalence to the reference product. Issues may include:

Active ingredient identity;
Salt form;
Dosage strength;
Capsule performance;
Dissolution;
Stability;
Impurity profile; and
Labeling restrictions.

Patent risks

Potential risks may arise from later patents covering a formulation, method of use, process, or other product characteristic. Those rights must be reviewed in the current Orange Book and relevant patent-family records.

Commercial risks

Tamsulosin is an established generic market with multiple suppliers. Commercial exposure depends on:

Generic price erosion;
Number of approved suppliers;
Pharmacy benefit-manager contracting;
Wholesaler inventory;
Authorized-generic competition;
Supply reliability; and
Product differentiation.

Patent 4,731,478 does not provide an active basis for preserving branded pricing.

How does Patent 4,731,478 compare with a formulation patent?

The distinction is material.

Issue	Patent 4,731,478	Typical formulation patent
Primary subject	Active chemical entity	Drug-delivery system
Key limitation	Molecular structure and stereochemistry	Release, excipients, dosage form, or manufacturing parameters
Design-around potential	Low during term if active ingredient is required	Often higher through alternative formulations
Product coverage	Broad across ordinary dosage forms	Narrower but potentially longer-lived
Current status	Expired	Must be checked patent by patent

The core compound patent generally provides the strongest exclusionary position because it reaches the active ingredient independent of formulation design. Once it expires, formulation patents become the principal source of residual patent risk.

Key Takeaways

U.S. Patent 4,731,478 is the foundational U.S. patent for tamsulosin.
Claim 1 covers the optically active form of the specified sulfonamide compound.
Claim 2 specifically covers the negative enantiomer used commercially as tamsulosin.
Claims 3 and 4 cover pharmaceutical compositions containing the active compound or negative isomer.
The patent issued March 15, 1988, and its ordinary term expired March 15, 2005.
The claims do not expressly recite a specific dose, capsule, excipient, release profile, polymorph, or manufacturing process.
Tamsulosin hydrochloride coverage depends on claim construction and the relationship between the salt and active moiety.
Patent 4,731,478 cannot currently block generic tamsulosin entry in the United States.
Current patent risk must be assessed through later formulation, method-of-use, salt, and process patents.
Historical Paragraph IV litigation does not create present enforceability after expiration.

FAQs

Does U.S. Patent 4,731,478 cover tamsulosin hydrochloride?

It covers the tamsulosin active structure and may reach tamsulosin hydrochloride depending on claim construction. The supplied claims do not expressly recite "hydrochloride."

Is Patent 4,731,478 still enforceable?

No. Its ordinary U.S. patent term expired on March 15, 2005.

Does the patent cover both R-tamsulosin and S-tamsulosin?

Claim 1 uses the broader term "optically active," while claim 2 specifically identifies the negative isomer. The negative enantiomer is the commercially relevant tamsulosin form.

Can a generic company avoid the patent by using a different excipient?

That strategy would not have avoided the compound claims during the patent term. A composition containing the claimed active compound could still have implicated claims 3 or 4.

Are tamsulosin formulation patents still relevant after the compound patent expired?

Yes. A later patent may cover a specific modified-release system, dosage form, process, or method of use even though the foundational compound patent has expired.

References

United States Patent and Trademark Office. (1988). U.S. Patent No. 4,731,478, Optically active phenylalkylamine derivatives.
U.S. Food and Drug Administration. (n.d.). Flomax (tamsulosin hydrochloride) prescribing information, NDA 020579.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	55-14382	Feb 08, 1980

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0034432	⤷ Start Trial	SPC/GB96/017: EXPIRE	United Kingdom	⤷ Start Trial
European Patent Office	0034432	⤷ Start Trial	96C0048	Belgium	⤷ Start Trial
Argentina	227533	⤷ Start Trial
Argentina	230433	⤷ Start Trial
Austria	7223	⤷ Start Trial
Australia	541720	⤷ Start Trial
Australia	6689681	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,731,478

Summary for Patent: 4,731,478